Summary
This paediatric clinical study examined G-CSF treatment outcomes in hospitalised infants with neutropenia, finding that whilst G-CSF accelerated hematologic recovery, it was associated with increased odds of secondary sepsis and mortality. The authors conclude that routine G-CSF use is not advisable in this population, suggesting potential harm outweighs the benefit of faster haematologic normalisation. The findings challenge conventional use of this growth factor in neonatal neutropenia management.
UK applicability
UK neonatal intensive care units and paediatric haematology services would find these safety findings directly applicable to clinical decision-making around G-CSF use in neutropenic infants, potentially informing NICE guidance and NHS practice protocols for this vulnerable population.
Key measures
Time to hematologic recovery; incidence of secondary sepsis; mortality rate
Outcomes reported
The study evaluated the effectiveness of G-CSF treatment on time to hematologic recovery and adverse outcomes (secondary sepsis and mortality) in hospitalised infants with neutropenia. Primary outcomes included haematologic recovery time; secondary outcomes included rates of secondary sepsis and all-cause mortality.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.